<DOC>
	<DOCNO>NCT00763555</DOCNO>
	<brief_summary>This multicenter , randomize , vehicle-controlled , double-blind parallel group study evaluate efficacy safety CD 2027 Oily Spray apply twice daily 8 week subject plaque-type psoriasis .</brief_summary>
	<brief_title>Efficacy Safety Study CD 2027 Spray Subjects With Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Subject diagnosis plaquetype psoriasis 20 % body surface area ( BSA ) involve exclude scalp , Global Severity Score least 3 ( moderate ) Screening Subject present representative target lesion least 16 cmÂ² area , locate nonbony area skin , Scaling Score 2 ( moderate ) , DSS least 4 Other type psoriasis ( plaque ) Significant abnormal lab finding Hypercalcemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>spray</keyword>
	<keyword>calcitriol</keyword>
</DOC>